Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,016 matching trials from the live ClinicalTrials.gov search.
Filters: "chemoradiation" Clear all
Recruiting Phase 1 Interventional

Adaptive Radiation Boost for Rectal Cancer

NCT07221058
View directory record Official record
Conditions
Rectum Cancer, Adenocarcinoma
Interventions
Adaptive Radiotherapy Boost
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

NCT01711658
View directory record Official record
Conditions
Non-HPV Locally Advanced Head and Neck Cancer
Interventions
IMRT, Cisplatin, placebo, Lapatinib
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting Phase 3 Interventional

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864
View directory record Official record
Conditions
Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
volrustomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott Valley, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

NCT07290621
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Toripalimab, Carboplatin, Paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

NCT00482014
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
pemetrexed, cisplatin, carboplatin, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Los Angeles, California • Wichita, Kansas • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Oct 15, 2026, 5:57 PM EDT
Terminated Not applicable Interventional

EMST and Swallowing in Long-Term Survivors of HNCA

NCT03975465
View directory record Official record
Conditions
Head and Neck Neoplasms, Deglutition Disorders
Interventions
Expiratory Muscle Strength Training, Pharyngeal Muscle Strengthening Exercises
Behavioral
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

NCT00602602
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
bevacizumab, fluorouracil, gemcitabine hydrochloride, oxaliplatin, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, endoscopic biopsy, laparoscopy, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 15, 2026, 5:57 PM EDT
Active, not recruiting Early Phase 1 Interventional

Bladder Preservation or Cystectomy for MIBC

NCT07821177
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
Interventions
Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Not applicable Interventional Results available

FLT PET/CT for Staging, Target Definition and Assessment of Response to Therapy in Patients With Esophageal Cancer

NCT01243619
View directory record Official record
Conditions
Esophageal Cancer
Interventions
3'-deoxy-3'-(18) F-fluorothymidine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 15, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

NCT03527264
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nivolumab induction, Cisplatin, Radiation, Nivolumab with chemoradiation, Nivolumab maintenance
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer

NCT01507428
View directory record Official record
Conditions
Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
18F-Fluoromisonidazole, Carboplatin, Computed Tomography, External Beam Radiation Therapy, Fludeoxyglucose F-18, Image-Guided Adaptive Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Positron Emission Tomography
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
29
States / cities
Palo Alto, California • Augusta, Georgia • Chicago, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting Phase 1 Interventional

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

NCT05819892
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Paclitaxel, Carboplatin, Dostarlimab, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

NCT00638612
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
AdV-tk, Valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Duarte, California • La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07219212
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
JNJ-90301900, Cisplatin, Intensity Modulated Radiation Therapy (IMRT), Carboplatin, Paclitaxel
Drug · Radiation
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 3 Interventional Results available

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT00884741
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Temozolomide
Radiation · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
324
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting Phase 3 Interventional

A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer

NCT06563479
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma
Interventions
FMISO-PET Scan, Chemoradiation, Assessments
Diagnostic Test · Combination Product · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer

NCT00114231
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, neoadjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
67
States / cities
Scottsdale, Arizona • Concord, California • Duarte, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 15, 2026, 5:57 PM EDT
Terminated Phase 3 Interventional Results available

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

NCT02952586
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Avelumab, Chemoradiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
139
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 15, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemoradiation for Resectable Glioblastoma

NCT04209790
View directory record Official record
Conditions
Glioblastoma, Surgery, High Grade Glioma
Interventions
Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)
Radiation · Drug · Procedure
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting No phase listed Observational

Retrospective Review of Esophageal Cancer at MSKCC

NCT05706558
View directory record Official record
Conditions
Esophageal Cancer, Esophagus Cancer
Interventions
Esophagectomy
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trimodality Management of T1b Esophageal Cancers

NCT01217060
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Docetaxel, 5-FU, Radiotherapy, Esophagectomy, Dexamethasone
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 15, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC

NCT04042935
View directory record Official record
Conditions
HNSCC
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

NCT03801876
View directory record Official record
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Capecitabine, Carboplatin, Computed Tomography, Docetaxel, Esophagectomy, Fluorouracil, Intensity-Modulated Radiation Therapy, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2036
U.S. locations
96
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 15, 2026, 5:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05639972
View directory record Official record
Conditions
HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 5:57 PM EDT